Study of the pharmacokinetics of various drugs under conditions of antiorthostatic hypokinesia and the pharmacokinetics of acetaminophen under long-term spaceflight conditions
Author:
Polyakov Alexey V.1, Svistunov Andrey A.2, Kondratenko Svetlana N.2, Kovachevich Irina V.1, Repenkova Lyudmila G.1, Savelyeva Marina I.3, Shikh Evgenia V.2, Badriddinova Lidiya Y.2
Affiliation:
1. Laboratory for the Development of Means and Methods of Medical Care in Extreme Conditions and Telemedicine of the State Scientific Centre of the Russian Federation, Institute of Medical and Biological Problems of the Russian Academy of Sciences , Moscow , Russian Federation 2. Department of Clinical Pharmacology and Propaedeutics of Internal Diseases , Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia , Moscow , Russian Federation 3. Department of Clinical Pharmacology and Therapy , Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia , Moscow , Russian Federation
Abstract
Abstract
Objectives
To study the pharmacokinetics and relative bioavailability of drugs of different chemical structure and pharmacological action under conditions simulating the effects of some factors of spaceflight, as well as the peculiarities of the pharmacokinetics of acetaminophen under long-term spaceflight conditions.
Methods
The pharmacokinetics of verapamil (n=8), propranolol (n=8), etacizine (n=9), furosemide (n=6), and acetaminophen (n=7) in healthy volunteers after a single oral administration under normal conditions (background) and under antiorthostatic hypokinesia (ANOH), the pharmacokinetics of acetaminophen in spaceflight members under normal ground conditions (background) (n=8) and under prolonged spaceflight conditions (SF) (n=5) were studied.
Results
The stay of volunteers under antiorthostatic hypokinesia had different effects on the pharmacokinetics and bioavailability of drugs: Compared to background, there was a decreasing trend in Vz for verapamil (−54 Δ%), furosemide (−20 Δ%), propranolol (−8 Δ%), and acetaminophen (−9 Δ%), but a statistically significant increase in Vz was found for etacizine (+39 Δ%); there was an increasing trend in Clt for propranolol (+13 Δ%) and acetaminophen (+16 Δ%), and a decreasing trend in Clt for etacizine, verapamil, and furosemide (−22, −23 and −9 Δ% respectively) in ANOH. The relative bioavailability of etacizine, verapamil, and furosemide in ANOH increased compared to background (+40, +23 and +13 Δ%, respectively), propranolol and acetaminophen decreased (−5 and −12 Δ% accordingly). The relative rate of absorption of etacizine and furosemide in ANOH decreased (−19 and −20 Δ%, respectively) while that of verapamil, propranolol, and acetaminophen increased (+42, +58 and +26 Δ%, respectively). A statistically significant decrease in AUC0-∞ (−57 Δ%), Cmax (−53 Δ%), relative bioavailability of acetaminophen (−52 Δ%) and a sharp increase in Clt (+147 Δ%), Tmax (+131 Δ%) as well as a trend towards a significant decrease in T1/2 (−53 Δ%), MRT (−36 Δ%) and a moderate increase in Vz (+24 Δ%) were found under control compared to background. Unidirectional changes in AUC0-∞, Clt, T1/2, MRT and relative bioavailability of acetaminophen, which are more pronounced in SF and opposite dynamics for Cmax, Tmax, Vz were found in ANOH and SP compared to background studies.
Conclusions
The data obtained allow recommending the studied drugs for rational pharmacotherapy in the possible development of cardiovascular disease in manned spaceflight.
Publisher
Walter de Gruyter GmbH
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference35 articles.
1. Blue, RS, Bayuse, TM, Daniels, VR, Wotring, VE, Suresh, R, Mulcahy, RA, et al.. Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. NPJ Microgravity 2019;5:14. https://doi.org/10.1038/s41526-019-0075-2. 2. Blue, RS, Chancellor, JC, Antonsen, EL, Bayuse, TM, Daniels, VR, Wotring, VE. Limitations in predicting radiation-induced pharmaceutical instability during long-duration spaceflight. NPJ Microgravity 2019;5:15. https://doi.org/10.1038/s41526-019-0076-1. 3. Braddock, M. Ergonomic challenges for astronauts during space travel and the need for space medicine. J Ergon 2017;7:221. https://doi.org/10.4172/2165-7556.1000221. 4. Eyal, S. How do the pharmacokinetics of drugs change in astronauts in space? Expet Opin Drug Metabol Toxicol 2020;16:353–6. https://doi.org/10.1080/17425255.2020.1746763. 5. Kast, J, Yu, Y, Seubert, CN, Wotring, VE, Derendorf, H. Drugs in space: pharmacokinetics and pharmacodynamics in astronauts. Eur J Pharmaceut Sci 2017;109S:S2–8. https://doi.org/10.1016/j.ejps.2017.05.025.
|
|